Tempus Ai

Tempus Ai company information, Employees & Contact Information

Explore related pages

Related company profiles:

Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. We enable physicians to make real-time, data-driven decisions to deliver personalized care and targeted therapies for patients through our analytical machine learning platform that uses the power of artificial intelligence in healthcare. We also work with partners to facilitate discovery, development, and delivery of optimized therapeutic options for patients through distinctive solution sets. Our mission is for each patient to benefit from the treatment of others who came before by providing the healthcare industry tools that learn as we gather more data. It’s About Time. For more information, visit tempus.com and follow us on Twitter (@TempusLabs).

Company Details

Employees
2.83K
Founded
-
Address
600 West Chicago Avenue, Suite 510,spain
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
tempus.com
HQ
Chicago, IL
Looking for a particular Tempus Ai employee's phone or email?

Tempus Ai Questions

News

Tempus to Participate in the Stifel 2025 Healthcare Conference - Business Wire

Tempus to Participate in the Stifel 2025 Healthcare Conference Business Wire

Tempus to Report Third Quarter 2025 Financial Results on November 4 - FinancialContent

Tempus to Report Third Quarter 2025 Financial Results on November 4 FinancialContent

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation - Illumina

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation Illumina

Tempus to Report Third Quarter 2025 Financial Results on November 4 - Business Wire

Tempus to Report Third Quarter 2025 Financial Results on November 4 Business Wire

Geneva Watch Days 2025: GMT and WorldTempus Party - en.worldtempus.com

Geneva Watch Days 2025: GMT and WorldTempus Party en.worldtempus.com

Tempus to Present at the William Blair 45th Annual Growth Stock Conference - Yahoo Finance

Tempus to Present at the William Blair 45th Annual Growth Stock Conference Yahoo Finance

Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research - Business Wire

Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research Business Wire

Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy - Business Wire

Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy Business Wire

Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025 - Business Wire

Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025 Business Wire

Tempus Reports Second Quarter 2025 Results - Business Wire

Tempus Reports Second Quarter 2025 Results Business Wire

Tempus Announces the Acquisition of Paige - Business Wire

Tempus Announces the Acquisition of Paige Business Wire

Northwestern Medicine Becomes First Health System to Integrate Tempus’ Generative AI Co-Pilot, David, Into Its EHR Platform - Business Wire

Northwestern Medicine Becomes First Health System to Integrate Tempus’ Generative AI Co-Pilot, David, Into Its EHR Platform Business Wire

Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device - Business Wire

Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device Business Wire

Tempus Announces New Study in JCO Precision Oncology Validating PurIST - Business Wire

Tempus Announces New Study in JCO Precision Oncology Validating PurIST Business Wire

Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform - Business Wire

Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform Business Wire

Introducing Tempus One in the EHR with Integrated Guidelines - Business Wire

Introducing Tempus One in the EHR with Integrated Guidelines Business Wire

Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry - Business Wire

Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry Business Wire

Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model - Business Wire

Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model Business Wire

Tempus Reports First Quarter 2025 Results - Business Wire

Tempus Reports First Quarter 2025 Results Business Wire

Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers - Business Wire

Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers Business Wire

Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes - Business Wire

Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes Business Wire

Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting - Business Wire

Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting Business Wire

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense - Business Wire

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense Business Wire

Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment - Business Wire

Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment Business Wire

Tempus Announces Collaboration with Northwestern University’s Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer’s Disease Research - Business Wire

Tempus Announces Collaboration with Northwestern University’s Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer’s Disease Research Business Wire

Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology - Business Wire

Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology Business Wire

Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S. - Business Wire

Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S. Business Wire

Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – What Investors Need to Know - ts2.tech

Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – What Investors Need to Know ts2.tech

Tempus Announces the National Launch of FDA-Approved xT CDx Test - Yahoo Finance

Tempus Announces the National Launch of FDA-Approved xT CDx Test Yahoo Finance

Tempus Reports Fourth Quarter and Full Year 2024 Results - Business Wire

Tempus Reports Fourth Quarter and Full Year 2024 Results Business Wire

Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions - Yahoo Finance

Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions Yahoo Finance

Tempus One Introduces New GenAI Capabilities to Query Millions of Unstructured Documents for Research and Clinical Care - Business Wire

Tempus One Introduces New GenAI Capabilities to Query Millions of Unstructured Documents for Research and Clinical Care Business Wire

Ares Management Upsizes Tempus Debt Facilities to $560 Million - Business Wire

Ares Management Upsizes Tempus Debt Facilities to $560 Million Business Wire

Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics - Business Wire

Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics Business Wire

Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease - Yahoo Finance

Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease Yahoo Finance

Tempus Announces Pricing of Initial Public Offering - Business Wire

Tempus Announces Pricing of Initial Public Offering Business Wire

GSK announces expanded collaboration with Tempus in precision medicine to accelerate R&D - GSK

GSK announces expanded collaboration with Tempus in precision medicine to accelerate R&D GSK

Tempus Announces Broad Launch of Tempus One - Business Wire

Tempus Announces Broad Launch of Tempus One Business Wire

Validation of a transcriptome-based assay for classifying cancers of unknown primary origin - medRxiv

Validation of a transcriptome-based assay for classifying cancers of unknown primary origin medRxiv

Tempus Introduces AI-enabled Assistant, Tempus One, Into Lens Data Analytics Platform to Accelerate Research - The AI Journal

Tempus Introduces AI-enabled Assistant, Tempus One, Into Lens Data Analytics Platform to Accelerate Research The AI Journal

WorldTempus Team Test - en.worldtempus.com

WorldTempus Team Test en.worldtempus.com

Tempus Announces the GEMINI Non-Small Cell Lung Cancer Study - FinancialContent

Tempus Announces the GEMINI Non-Small Cell Lung Cancer Study FinancialContent

Tempus and University of California Davis Comprehensive - GlobeNewswire

Tempus and University of California Davis Comprehensive GlobeNewswire

Tempus and Mayo Clinic Team Up to Personalize Care for Cancer Patients - PR Newswire

Tempus and Mayo Clinic Team Up to Personalize Care for Cancer Patients PR Newswire

Top Tempus Ai Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant